主旨:訂定「食品過敏原標示規定」,並自中華民國一百零四年七月一日生效。依據:食品安全衛生管理法第二十二條第一項第十款。
 
公告事項:
 
一、市售有容器或包裝之食品,含有下列對特殊過敏體質者致生過敏之內容物,應於其容器或外包裝上,顯著標示含有致過敏性內容物名稱之醒語資訊:
 
(一)蝦及其製品。
(二)蟹及其製品。
(三)芒果及其製品。
(四)花生及其製品。
(五)牛奶及其製品;由牛奶取得之乳糖醇(lactitol),不在此限。
(六)蛋及其製品。
 
二、前項醒語資訊,應載明「本產品含有○○」、「本產品含有○○,不適合其過敏體質者食用」或等同意義字樣。
 
資料來源:衛生福利部食品衛生管理署 Read more

Incredible break-though stem cell technology combined with patented Mac-5 Complex has top model and actress Joanna Krupa excited. Cellogica is offering a risk free trial to anyone curious to see what Joanna is so excited about that can be claimed at http://xacey.com/cellogica.

Preston, Idaho, March 24, 2014 -- Joanna Krupa, top model and actress, depends on looking good for her career. Tired of trying creams and lotions that did  not do what ... Read more

Vitality Detox Retreats are giving a “Last Minute” 15% discount on their 7 day Spring Detox retreat which runs from 2– 9 May 2014. Spring is the optimal time for doing a detox. Chichester, West Sussex, UK, April 30, 2014 -- Vitality Detox Retreats are offering a great deal on their upcoming UK retreat because Spring has always been the favoured time for cleansing and detoxification in the traditional natural health care practices. Naturopathy, Ayurveda, ... Read more

Myweightlossdream.co.uk has released a new nutrifit clean eating review that will help customers learn more about this diet and fitness plan that comes with an eBook. Portugal, May 09, 2014 -- Myweightlossdream.co.uk has released a new nutrifit clean eating review that will help customers learn more about this diet and fitness plan that comes with an eBook. From this review, people will learn whether ... Read more

Hoping to make a difference in people's lives, Gregory Ripley has opened Primal Health & Wellness, an acupuncture clinic in Minnetonka, MN. For many years Gregory has been looking for different ways to help people rediscover the original state of health and wellness that we are born with. He looks forward to continuing this work through his acupuncture practice. Minnetonka, MN, May 22, 2014 /PressReleasePing/ - Gregory Ripley, L.Ac., recently opened a new acupuncture practice in ... Read more

 متوفر لدينا الان فياجرا 50 مليجرام -  انتاج شركة فايزر
  Read more

Medicine Store Company- شركة ميديسن ستور
متوفر لدينا بندكس اقراص و شراب Read more

Myweightlossdream.co.uk is a new blog that teaches bloggers how to start a weight loss blog by themselves. Portugal, June 10, 2014 -- Myweightlossdream.co.uk is a new blog that teaches bloggers how to start a weight loss blog by themselves. There are many secrets, which can greatly increase their success in selling their weight loss products, if they are properly applied. This new blog will provide the visitors with helpful advices and tips on how to get constant income stream by building a ... Read more

 
 
Biotech News Alert: GenSpera (OTCQB:GNSZ) to Present at Rodman & Renshaw 16th Annual Global Investment Conference
 
CEO to Present Significance of Announced Clinical Trial Results for Lead Drug G-202 Treating Hepatocellular Carcinoma (HCC) Patients to Wall Street Audience
 
SAN ANTONIO, Texas, August 14, 2014 –  (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, ... Read more

GenSpera (OTCQB:GNSZ) Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids

 

SAN ANTONIO - August 28, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the recent publication of the article "Targeting thapsigargin towards tumors" in the journal Steroids.

  ... Read more

Biotech News Alert: GenSpera (OTCQB:GNSZ) Announces Generic Name “Mipsagargin” for Lead Drug Candidate G-202 per Recommendation by World Health Organization
 

Mipsagargin Contains New Pre-Stem “Gargin”, Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market

 

SAN ANTONIO, Texas, September 3, 2014 – (Investorideas.com Biotech Newswire) GenSpera, Inc. ( ... Read more

Biotech News Alert: GenSpera (OTCQB:GNSZ) Announces Generic Name “Mipsagargin” for Lead Drug Candidate G-202 per Recommendation by World Health Organization
 

Mipsagargin Contains New Pre-Stem “Gargin”, Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market

 

SAN ANTONIO, Texas, September 3, 2014 – (Investorideas.com Biotech Newswire) GenSpera, Inc. ( ... Read more

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform

 

SAN DIEGO and PRINCETON, N.J. - September 8, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that ESI researchers have ... Read more

Tenak Africa

Complete tender materials – from all manufactures. TENAK Africa has several years of experience as a 'one stop supplier' of laboratory equipment and consumables in Africa. TENAK Africa has through many years build strong partnerships with both world wide suppliers and business partners in Africa.
Biotech News Alert: GenSpera (OTCQB:GNSZ) Announces US Patent for Methods and Compositions for the Detection, Imaging and Treatment of Cancer
 
SAN ANTONIO - July 30, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the issuance of a United States patent entitled "Methods and compositions for the detection of cancer". The patent US 8,772,226 B2 was issued July 8, 2014.
  ... Read more

GenSpera's (OTCQB:GNSZ) CEO Shares Insight on Unique Properties and Targeting of Lead Drug G-202, Based on the Thapsigargin Toxin

Dr. Craig A. Dionne, PhD, President and CEO  - Corporate Video
Biotech News Alert: GenSpera's (OTCQB:GNSZ) CEO Shares Insight on Unique Properties and Targeting of Lead Drug G-202, Based on the Thapsigargin Toxin
 
POINT ROBERTS, Wash. and NEW YORK - August 5, 2014 (Investorideas.com Biotech Newswire) Investorideas.com, a global news source covering leading sectors including biotech, issues an exclusive Q&A interview with Dr. Craig Dionne, PhD, GenSpera's (OTCQB:GNSZ) CEO. Dr. Dionne discusses the company's lead drug G-202 and how they have ... Read more

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) CEO Note: A Novel Strategy To Address Ebola
 
SAN DIEGO - August 6, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
 
The current ebola outbreak in West Africa demonstrates the urgent need for therapeutic strategies to defend against emerging pandemic threats. It also highlights why the Department of Health ... Read more

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Receipt of IRB Approval to Initiate Hemopurifier™ Clinical Studies

 

SAN DIEGO - September 2, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has ... Read more

Biotech News Alert: GenSpera (OTCQB:GNSZ) Presents Mipsagargin (G-202) HCC Clinical Trial Update at 8th International Liver Cancer Association Conference

 

50% of Patients Treated with Mipsagargin had No Tumor Growth at Four Months

 

SAN ANTONIO - September 8, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing ... Read more

Biotech News Alert: GenSpera (OTCQB:GNSZ) Receives Patent on Prodrug Targeted for Prostate Cancer

 

SAN ANTONIO - September 9, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs." ... Read more

Medical Technology Breaking News: Aethlon Medical, Inc. (OTCQB: AEMD) - "The Identification of Neurological Disorders in NFL Players"

 

New York, NY - September 16, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD) today published a new blog post on The Chairman’s Blog, written by the Company’s Chairman and Chief Executive Officer, James A Joyce. TheChairmansBlog.com is an ... Read more

Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) and Exosome Sciences Announce Clinical Collaboration with Boston University CTE Center To Advance Diagnostic Candidate to Detect CTE in Former NFL Players

 

SAN DIEGO, PRINCETON, N.J. and BOSTON - September 26, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD) and its diagnostic subsidiary, Exosome Sciences, Inc. ( ... Read more

Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces Dengue Virus Treatment Agreement

 

SAN DIEGO - September 25, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into an agreement with ... Read more

Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces Undetectable Ebola Virus in Patient Treated with Hemopurifier® Therapy

 

SAN DIEGO - November 6, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, announced today that officials at Frankfurt University ... Read more

Medical Technology Breaking News: Aethlon Medical's (OTCBB: AEMD) Hemopurifier® Used in Successful Treatment of Patient with Advanced Ebola Infection

 

242 Million Copies of Ebola Virus Removed from Patient during Treatment, Physician Reports at American Society of Nephrology Annual Meeting

 

SAN DIEGO and PHILADELPHIA - November 14, 2014 (Investorideas.com newswire) The Aethlon Hemopurifier® was used in the ... Read more

Medical Technology Breaking News: Ebola Patient Who Received Aethlon (OTCBB: AEMD) Hemopurifier® Therapy Has Been Discharged From Hospital

 

SAN DIEGO - November 25, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, disclosed today that an Ebola patient who received Hemopurifier® ... Read more

Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces First Hemopurifier® Shipment To Support the Treatment of Ebola in the United States

 

SAN DIEGO - November 26, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today announced the first shipment of ... Read more

Biotech News Alert: GenSpera (OTCQB:GNSZ) Announces Completion of Patient Enrollment in the Phase II Clinical Trial of Mipsagargin in Liver Cancer Patients

 

SAN ANTONIO - October 9, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that patient enrollment has been completed in the ... Read more

Pages